MUC16 and neoplasm: Preclinical studies suggest that combining a CD3-engaging TCE with a CD28 bispecific greatly enhances T-cell proliferation and tumor eradication, without systemic T-cell overactivation, as co-stimulation is restricted to MUC16-positive tumor cells [202].